Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | IDE | P14735 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18222546 | 0.90 | HTR6 (0.47) | HTR6ALKPDE4APDE4BPDE4C | |
| SCHEMBL18239785 | 0.88 | HTR6 (0.48) | HTR6ALKPPARGPPARDPPARA | |
| SCHEMBL28100864 | 0.80 | MTNR1A (0.44) | HTR6PPARGPPARDPPARA | |
| SCHEMBL18239764 | 0.79 | SMN1; SMN2 (0.38) | HTR6ALKPDE4APDE4BPDE4C | |
| SCHEMBL18222527 | 0.78 | HTR6 (0.50) | HTR6PPARGPPARDPPARA | |
| SCHEMBL3012635 | 0.75 | HTR6 (0.55) | HTR6ALKPPARGPPARDPPARA | |
| SCHEMBL18222505 | 0.75 | HTR6 (0.43) | HTR6ALKPPARGPPARDPPARA | |
| SCHEMBL18800001 | 0.74 | MTNR1A (0.38) | — | |
| SCHEMBL14605614 | 0.74 | PPARG (0.61) | HTR6ALKPDE4APDE4BPDE4C | |
| SCHEMBL18239683 | 0.73 | MTNR1A (0.43) | HTR6ALKPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637451-B2 | Indole compound | ASTELLAS PHARMA INC. (JP) | 2017-05-02 | — | — | US | disclosed |
| EP-3095781-A1 | INDOLE COMPOUND | Astellas Pharma Inc. (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-20160332966-A1 | INDOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332966-A1 | INDOLE COMPOUND | MTNR1A, MTNR1B, IDO2 | HTR6 129/4885ALK 4144/4885PDE4A 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.